Page last updated: 2024-10-19
melatonin and Response Evaluation Criteria in Solid Tumors
melatonin has been researched along with Response Evaluation Criteria in Solid Tumors in 1 studies
Response Evaluation Criteria in Solid Tumors: An internationally recognized set of published rules used for evaluation of cancer treatment that define when tumors found in cancer patients improve, worsen, or remain stable during treatment. These criteria are based specifically on the response of the tumor(s) to treatment, and not on the overall health status of the patient resulting from treatment.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| "Melatonin has a powerful antioxidant and oncostatic effects that are expected to improve tumor hypoxia and clinical response." | 2.94 | Effect of melatonin supplementation in combination with neoadjuvant chemotherapy to miR-210 and CD44 expression and clinical response improvement in locally advanced oral squamous cell carcinoma: a randomized controlled trial. ( Abdullah, M; Haryana, SM; Jusman, SW; Kartini, D; Maruli, H; Panigoro, SS; Purwanto, DJ; Rustamadji, P; Setiabudy, R; Siregar, BH; Sungkar, S; Suroyo, I; Sutandyo, N; Taher, A, 2020) |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Kartini, D | 1 |
| Taher, A | 1 |
| Panigoro, SS | 1 |
| Setiabudy, R | 1 |
| Jusman, SW | 1 |
| Haryana, SM | 1 |
| Abdullah, M | 1 |
| Rustamadji, P | 1 |
| Purwanto, DJ | 1 |
| Sutandyo, N | 1 |
| Suroyo, I | 1 |
| Siregar, BH | 1 |
| Maruli, H | 1 |
| Sungkar, S | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| Effect of Melatonin in Combination With Neoadjuvant Chemotherapy to HIF-1⍺, CD44, CD133, and miR-210 Expression and Clinical Response in Locally Advanced Oral Squamous Cell Carcinoma (OSCC)[NCT04137627] | Phase 3 | 50 participants (Actual) | Interventional | 2017-07-04 | Completed |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Change in Expression of CD133 as Measured by qRT-PCR Absolute Quantification
Expression of CD133 is measured at the initial period of the study (baseline) and after 3 neoadjuvant chemotherapy cycles are completed using qRT-PCR Absolute Quantification. Change was calculated from two time points as the value at the later time point minus the value at the earlier time point. (NCT04137627)
Timeframe: 1 Year
| Intervention | Picogram/microliter (Median) |
|---|
| Pre-Treatment | Post-Treatment | Change (Posttreatment - Pretreatment) |
|---|
| Melatonin | 1.13 | 1.42 | 0.43 |
,| Placebo | 1.07 | 1.88 | 0.55 |
Change in Expression of CD44 as Measured by qRT-PCR Absolute Quantification
Expression of CD44 is measured at the initial period of the study (baseline) and after 3 neoadjuvant chemotherapy cycles are completed using qRT-PCR Absolute Quantification. Change was calculated from two time points as the value at the later time point minus the value at the earlier time point. (NCT04137627)
Timeframe: 1 Year
| Intervention | Picogram/microliter (Median) |
|---|
| Pre-Treatment | Post-Treatment | Change (Posttreatment - Pretreatment) |
|---|
| Melatonin | 0.0349 | 0.0115 | -0.0114 |
,| Placebo | 0.0095 | 0.0187 | 0.0082 |
Change in Expression of HIF-1⍺ as Measured by qRT-PCR Absolute Quantification
Expression of HIF-1⍺ is measured at the initial period of the study (baseline) and after 3 neoadjuvant chemotherapy cycles are completed using qRT-PCR Absolute Quantification. Change was calculated from two time points as the value at the later time point minus the value at the earlier time point. (NCT04137627)
Timeframe: 1 Year
| Intervention | Picogram/microliter (Median) |
|---|
| Pre-Treatment | Post-Treatment | Change (Posttreatment - Pretreatment) |
|---|
| Melatonin | 0.018 | 0.012 | -0.008 |
,| Placebo | 0.0048 | 0.0087 | 0.0027 |
Change in Expression of miR-210 as Measured by qRT-PCR Absolute Quantification
Expression of miR-210 is measured at the initial period of the study (baseline) and after 3 neoadjuvant chemotherapy cycles are completed using qRT-PCR Absolute Quantification. Change was calculated from two time points as the value at the later time point minus the value at the earlier time point. (NCT04137627)
Timeframe: 1 Year
| Intervention | Picogram/microliter (Mean) |
|---|
| Pre-Treatment | Post-Treatment | Change (Posttreatment - Pretreatment) |
|---|
| Melatonin | 162.8 | 53.8 | -109.09 |
,| Placebo | 175.2 | 53.5 | -103.71 |
Trials
1 trial available for melatonin and Response Evaluation Criteria in Solid Tumors